Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research7

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research7

FiltersClear all

Status

Recruiting1
Active, not recruiting4
Completed1
Terminated1

Study type

Interventional7

Phase

Phase 12
Phase 1/21
Phase 21
Phase 2/31
Phase 31
Not applicable1

Investigator

Despina Siolas2
Manish A Shah2
Alana Nguyen1
Mehraneh Dorna Jafari1
Uqba Khan1

Department

Medicine6
Surgery1

Condition

Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34
Multiple Myeloma32

Intervention type

Drug6
Device2
Biological1
Other1
Procedure1

Sponsor type

Industry3
Other academic2
NIH1
WCM (investigator-initiated)1

Start date

Has results posted1

Colonic Neoplasms×Clear all

Showing 1–7 of 7 studiesSort:

Active, not recruitingInterventional · Phase 3NCT03803553 ↗
Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer
Manish A ShahPI
Intervention
Drug: FOLFIRI Protocol · Other: ACTIVE SURVEILLANCE · Drug: Nivolumab Protocol · Drug: Encorafenib/Binimetinib/Cetuximab Protocol · Drug: Trastuzumab + Pertuzumab
Dates

FiltersClear all

Status

Recruiting1
Active, not recruiting4
Completed1
Terminated1

Study type

Interventional7

Phase

Phase 12
Phase 1/21
Phase 21
Phase 2/31
Phase 31
Not applicable1

Investigator

Despina Siolas2
Manish A Shah2
Alana Nguyen1
Mehraneh Dorna Jafari1
Uqba Khan1

Department

Medicine6
Surgery1

Condition

Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34
Multiple Myeloma32

Intervention type

Drug6
Device2
Biological1
Other1
Procedure1

Sponsor type

Industry3
Other academic2
NIH1
WCM (investigator-initiated)1

Start date

Has results posted1

Colonic Neoplasms×Clear all

Showing 1–7 of 7 studiesSort:

Active, not recruitingInterventional · Phase 3NCT03803553 ↗
Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer
Manish A ShahPI
Intervention
Drug: FOLFIRI Protocol · Other: ACTIVE SURVEILLANCE · Drug: Nivolumab Protocol · Drug: Encorafenib/Binimetinib/Cetuximab Protocol · Drug: Trastuzumab + Pertuzumab
Dates

Show all 50

Show fewer

Neoplasms32
Colitis, Ulcerative29
Atrial Fibrillation27
Carcinoma, Non-Small-Cell Lung27
Crohn Disease27
Recurrence27
COVID-1926
Myelodysplastic Syndromes26
Parkinson Disease24
Neoplasm Metastasis23
Obesity23
Colorectal Neoplasms19
HIV Infections19
Hematologic Neoplasms19
Cardiovascular Diseases18
Depression18
Non-alcoholic Fatty Liver Disease16
Overweight15
Lung Neoplasms14
Melanoma14
Cognitive Dysfunction13
Idiopathic Pulmonary Fibrosis13
Inflammatory Bowel Diseases13
Alzheimer Disease12
Leukemia12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Coronary Artery Disease11
Hypertension11
Hypertension, Pulmonary11
Lung Diseases, Interstitial11
Myeloproliferative Disorders11
Pulmonary Arterial Hypertension11
Stroke11
Chronic Pain10
Hemophilia A10
Leukemia, Myelomonocytic, Chronic10
Lymphoma, Follicular10
Lymphoma, Large B-Cell, Diffuse10
Urinary Bladder Neoplasms10
Burkitt Lymphoma9
Fibrosis9
Liver Diseases9
Carcinoma, Renal Cell8

Apr 2020 – Dec 2026 (est.)

Sponsor

The General Hospital Corporation (dba Massachusetts General Hospital)

Metastatic Colon CancerStage III Colon Cancer

Active, not recruitingInterventional · Phase 1NCT04046445 ↗

An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

Manish A ShahPI

Intervention: Drug: ATP128 · Drug: BI 754091 · Drug: VSV-GP128
Dates: Jul 2019 – May 2025 (est.)
Sponsor: AMAL Therapeutics

Colorectal CancerMSSStage IV Colon Cancer+3 more

Active, not recruitingInterventional · Phase 1NCT04704661 ↗

Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)

Despina SiolasPI

Intervention: Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Drug: Ceralasertib · Procedure: Computed Tomography · Procedure: Echocardiography Test · Procedure: Multigated Acquisition Scan · Procedure: Positron Emission Tomography · Biological: Trastuzumab Deruxtecan
Dates: Aug 2021 – Mar 2027 (est.)
Sponsor: National Cancer Institute

Advanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more

RecruitingInterventional · Phase 2/3NCT05174169 ↗

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Uqba KhanPI

Intervention: Device: Signatera test · Drug: mFOLFOX6 3-6 month · Drug: CAPOX 3 month · Drug: mFOLFIRINOX · Drug: mFOLFOX6 6 month · Drug: CAPOX 6 month
Dates: Jul 2022 – Mar 2029 (est.)
Sponsor: NRG Oncology

Stage III Colon Cancer

Active, not recruitingInterventional · Phase 1/2NCT05726864 ↗

First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Alana NguyenPI

Intervention: Drug: ELI-002 7P
Dates: Apr 2023 – Apr 2026
Sponsor: Elicio Therapeutics, Inc.

Pancreatic Ductal AdenocarcinomaColorectal CancerKRAS G12D+11 more

TerminatedInterventional · Not applicableNCT04964297 ↗

Evaluation of Ability to Detect Bowel Gas During Laparoscopic Right Colectomy With Intracorporeal Anastomosis

Mehraneh Dorna JafariPI

Intervention: Device: Obtaining bowel gas samples
Dates: Aug 2021 – Apr 2024· Results posted
Sponsor: Weill Medical College of Cornell University

Crohn's Disease of Large IntestineMalignant Neoplasm of Colon

CompletedInterventional · Phase 2NCT05480306 ↗

Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)

Despina SiolasPI

Intervention: Drug: DKN-01 · Drug: FOLFIRI · Drug: Bevacizumab · Drug: FOLFOX
Dates: Aug 2022 – Jul 2025
Sponsor: Leap Therapeutics, Inc.

Colorectal CancerColorectal AdenocarcinomaColo-rectal Cancer+1 more